Ad
related to: drugs that increase gi motility in men and prostate health articles
Search results
Results from the WOW.Com Content Network
Activation of a wide range of serotonin receptors by serotonin itself or by certain prokinetic drugs results in enhanced gastrointestinal motility. [3] Other prokinetic drugs may increase acetylcholine concentrations by stimulating the M 1 receptor which causes acetylcholine release, or by inhibiting the enzyme acetylcholinesterase which ...
Men reporting no sexual interest increased from 27.6% to 63.6% after orchiectomy, and from 31.7% to 58.0% after GnRH-A; men who experienced no erections increased from 35.0% to 78.6%; and men who did not report engaging in sexual activity increased from 47.9% to 82.8% after orchiectomy and 45.0% to 80.2%. [14]
Cisapride is a gastroprokinetic agent, a drug that increases motility in the upper gastrointestinal tract. It acts directly as a serotonin 5-HT 4 receptor agonist and indirectly as a parasympathomimetic. Stimulation of the serotonin receptors increases acetylcholine release in the enteric nervous system.
Prucalopride is contraindicated where there is hypersensitivity to the active substance or to any of the excipients, renal impairment requiring dialysis, intestinal perforation or obstruction due to structural or functional disorder of the gut wall, obstructive ileus, severe inflammatory conditions of the intestinal tract, such as Crohn's disease, and ulcerative colitis and toxic megacolon ...
The most common side effects reported with naltrexone are gastrointestinal complaints such as diarrhea and abdominal cramping. [3] These adverse effects are analogous to the symptoms of opioid withdrawal, as the μ-opioid receptor blockade will increase gastrointestinal motility. The side effects of naltrexone by incidence are as follows: [3]
[17] [18] [19] Phase I and II trials have provided preliminary evidence that the SARMs enobosarm and GSK-2881078 (in elderly men and postmenopausal women), and OPL-88004 (prostate cancer survivors with low levels of testosterone) increase lean body mass and muscle size with little effect on the prostate, supporting the potential of SARMs for ...
Recent studies reveal that diets rich in omega-3 fatty acids, particularly DHA, may slow down prostate cancer growth, while diets that promote inflammation might increase the risk of aggressive ...
Lutetium (177 Lu) vipivotide tetraxetan, sold under the brand name Pluvicto, is a radiopharmaceutical medication used for the treatment of prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC). [5] [6] Lutetium (177 Lu) vipivotide tetraxetan is a targeted radioligand therapy. [6] [8]
Ad
related to: drugs that increase gi motility in men and prostate health articles